{
    "clinical_study": {
        "@rank": "154658", 
        "arm_group": {
            "arm_group_label": "Patients on Ferriprox therapy <1 month"
        }, 
        "brief_summary": {
            "textblock": "Observational, open label, prospective, multi-center, post-marketing drug surveillance\n      program."
        }, 
        "brief_title": "Active Drug Surveillance Program of Ferriprox Use", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Transfusional Iron Overload", 
        "condition_browse": {
            "mesh_term": "Iron Overload"
        }, 
        "detailed_description": {
            "textblock": "A post-marketing, drug surveillance program evaluating the use, monitoring, benefits and\n      adverse effects of Ferriprox under clinical conditions in newly treated patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Patients who started Ferriprox therapy less than one month or are to initiate\n             Ferriprox therapy at the time of enrolment into the program.\n\n        Main Exclusion Criteria:\n\n          -  Patients treated with Ferriprox for more than one month prior to enrolment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Apporximately 300 patients who have recently started treatment with treatment with\n        Ferriprox (less than one month prior to enrolment) or who are naive to Ferriprox\n        treatment."
            }
        }, 
        "enrollment": {
            "#text": "294", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838291", 
            "org_study_id": "LA35-PM"
        }, 
        "intervention_browse": {
            "mesh_term": "Deferiprone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ferriprox", 
            "Deferiprone", 
            "DFP", 
            "L1"
        ], 
        "lastchanged_date": "April 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nicosia", 
                        "country": "Cyprus"
                    }, 
                    "name": "Thalassemia Center of North Cyprus Turkish Republic (KKTC)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alexandria", 
                        "country": "Egypt"
                    }, 
                    "name": "Hematology Unit, El-Shatby Children Hospital, Alexandria University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Assiut", 
                        "country": "Egypt"
                    }, 
                    "name": "Hematology Unit, Assiut University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cairo", 
                        "country": "Egypt"
                    }, 
                    "name": "Ain Shams University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mansoura", 
                        "country": "Egypt"
                    }, 
                    "name": "Hematology Unit, Mansoura University Children Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tanta", 
                        "country": "Egypt"
                    }, 
                    "name": "Tanta University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zagazig", 
                        "country": "Egypt"
                    }, 
                    "name": "Hematology/Oncology Unit ; Zagazig University Children Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zagazig", 
                        "country": "Egypt"
                    }, 
                    "name": "Zagazig University; Thalassemia Association"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muscat", 
                        "country": "Oman"
                    }, 
                    "name": "Department of Child Health, College of Medicine and Health Sciences, Sultan Qaboos University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeddah", 
                        "country": "Saudi Arabia"
                    }, 
                    "name": "King Abdulaziz University Hospital (KAAUH)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maddinah", 
                        "country": "Saudi Arabia"
                    }, 
                    "name": "Maternity and Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adana", 
                        "country": "Turkey"
                    }, 
                    "name": "\u00c7ukurova \u00dcniversitesi Tip Fak\u00fcltesi, \u00c7ocuk Hematolojie Bilim Dali"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antalya", 
                        "country": "Turkey"
                    }, 
                    "name": "Akdeniz \u00dcniversitesi Hastanesi, \u00c7ocuk Sa\u011fli\u011fi, Hematolojie Klini\u011fi"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey"
                    }, 
                    "name": "\u00cfstanbul \u00dcniversitesi Tip. Fak. Hastanesi, \u00c7ocuk Sa\u011fli\u011fi, Hematolojie Klini\u011fi"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Cyprus", 
                "Egypt", 
                "Oman", 
                "Saudi Arabia", 
                "Turkey"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Active Drug Surveillance Program of Ferriprox Use", 
        "overall_official": {
            "affiliation": "ApoPharma", 
            "last_name": "Fernando Tricta, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Evaluation of dose of Ferriprox includes the frequency of administration of chelator(s).", 
                "measure": "Evaluation of dose of Ferriprox, and if applicable concurrent chelator(s) in newly treated patients.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 12 Months"
            }, 
            {
                "description": "Evaluation of how Ferriprox is prescribed/received by the patient: as monotherapy, simultaneous with deferoxamine, alternate with deferoxamine, simultaneous with deferasirox, alternate with deferasirox.", 
                "measure": "Evaluation of regimen of Ferriprox administration, and if applicable concurrent chelator(s) in newly treated patients.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 12 Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838291"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Beneficial effects of Ferriprox will be assessed based on the changes in: serum ferritin and cardiac iron concentration as assessed by MRI T2*.", 
                "measure": "Assessment of the beneficial effects of Ferriprox based on the characterization of its use in clinical practice.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 12 Months"
            }, 
            {
                "description": "Adverse effects of Ferriprox will be assessed based on: frequency of absolute neutrophil count (ANC) monitoring, occurrence of neutropenia or agranulocytosis and occurrence of other adverse events (AEs) or adverse drug reactions (ADRs).", 
                "measure": "Assessment of the adverse effects of Ferriprox based on the characterization of its use in clinical practice.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to 12 Months"
            }
        ], 
        "source": "ApoPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ApoPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}